The metabolism of riboflavin in female patients with liver cirrhosis

Janos Zempleni, John R. Galloway, Donald B. McCormick

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The metabolism of vitamin B2 was studied in five female patients with liver cirrhosis of varying etiology. Following the oral administration of 40 mg (106.3 μmol) riboflavin, plasma concentrations of riboflavin and flavocoenzymes as well as urinary riboflavin excretion were analyzed over a period of 48 h. Results were compared to data obtained for healthy controls (Zempleni J. et al, Am. J Clin. Nutr., 1996 [15]). About 18% of the administered vitamin was recovered from patients' urine, indicating an absorption similar to healthy subjects (p > 0.05). The area under the riboflavin plasma concentration vs time curve was 1.2-fold larger among patients than controls, but the difference was not significant (p > 0.05). Riboflavin peak concentrations in plasma (315.6 nmol/l) and times when those concentrations were achieved (3.0 h) were similar to those found for healthy subjects (p > 0.05). Flavocoenzyme peak plasma concentrations were increased 1.4-fold above their baseline levels in cirrhotics which was equal to controls (p > 0.05). 7α-Hydroxyriboflavin was detected in the plasma of patients. Distribution and elimination kinetics of riboflavin were analyzed by using a two-compartment open model; the riboflavin plasma disposition rate constant of the patients (kα = 0. 7232 h-1; k(β) = 0.0627 h-1) were not different from controls (p > 0. 05). No differences between both groups were found regarding renal excretion (renal clearance, first-order rate constants for renal excretion; p > 0.05). In conclusion, patients with cirrhosis of varying etiology and varying medical treatment did not show alterations of riboflavin turnover.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalInternational Journal for Vitamin and Nutrition Research
Volume66
Issue number3
StatePublished - Nov 14 1996

Fingerprint

liver cirrhosis
Riboflavin
riboflavin
Liver Cirrhosis
metabolism
excretion
etiology
Healthy Volunteers
kidneys
renal clearance
medical treatment
Vitamins
oral administration
Oral Administration
vitamins
Fibrosis
urine
Urine
Kidney
kinetics

Keywords

  • Blood plasma
  • Liver cirrhosis
  • Pharmacokinetics
  • Riboflavin
  • Urine

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

The metabolism of riboflavin in female patients with liver cirrhosis. / Zempleni, Janos; Galloway, John R.; McCormick, Donald B.

In: International Journal for Vitamin and Nutrition Research, Vol. 66, No. 3, 14.11.1996, p. 237-243.

Research output: Contribution to journalArticle

@article{b91947fa527c43dca5f461d4a9cc4fe4,
title = "The metabolism of riboflavin in female patients with liver cirrhosis",
abstract = "The metabolism of vitamin B2 was studied in five female patients with liver cirrhosis of varying etiology. Following the oral administration of 40 mg (106.3 μmol) riboflavin, plasma concentrations of riboflavin and flavocoenzymes as well as urinary riboflavin excretion were analyzed over a period of 48 h. Results were compared to data obtained for healthy controls (Zempleni J. et al, Am. J Clin. Nutr., 1996 [15]). About 18{\%} of the administered vitamin was recovered from patients' urine, indicating an absorption similar to healthy subjects (p > 0.05). The area under the riboflavin plasma concentration vs time curve was 1.2-fold larger among patients than controls, but the difference was not significant (p > 0.05). Riboflavin peak concentrations in plasma (315.6 nmol/l) and times when those concentrations were achieved (3.0 h) were similar to those found for healthy subjects (p > 0.05). Flavocoenzyme peak plasma concentrations were increased 1.4-fold above their baseline levels in cirrhotics which was equal to controls (p > 0.05). 7α-Hydroxyriboflavin was detected in the plasma of patients. Distribution and elimination kinetics of riboflavin were analyzed by using a two-compartment open model; the riboflavin plasma disposition rate constant of the patients (kα = 0. 7232 h-1; k(β) = 0.0627 h-1) were not different from controls (p > 0. 05). No differences between both groups were found regarding renal excretion (renal clearance, first-order rate constants for renal excretion; p > 0.05). In conclusion, patients with cirrhosis of varying etiology and varying medical treatment did not show alterations of riboflavin turnover.",
keywords = "Blood plasma, Liver cirrhosis, Pharmacokinetics, Riboflavin, Urine",
author = "Janos Zempleni and Galloway, {John R.} and McCormick, {Donald B.}",
year = "1996",
month = "11",
day = "14",
language = "English (US)",
volume = "66",
pages = "237--243",
journal = "Internationale Zeitschrift fur Vitaminforschung. International journal of vitamin research. Journal international de vitaminologie",
issn = "0300-9831",
publisher = "Verlag Hans Huber",
number = "3",

}

TY - JOUR

T1 - The metabolism of riboflavin in female patients with liver cirrhosis

AU - Zempleni, Janos

AU - Galloway, John R.

AU - McCormick, Donald B.

PY - 1996/11/14

Y1 - 1996/11/14

N2 - The metabolism of vitamin B2 was studied in five female patients with liver cirrhosis of varying etiology. Following the oral administration of 40 mg (106.3 μmol) riboflavin, plasma concentrations of riboflavin and flavocoenzymes as well as urinary riboflavin excretion were analyzed over a period of 48 h. Results were compared to data obtained for healthy controls (Zempleni J. et al, Am. J Clin. Nutr., 1996 [15]). About 18% of the administered vitamin was recovered from patients' urine, indicating an absorption similar to healthy subjects (p > 0.05). The area under the riboflavin plasma concentration vs time curve was 1.2-fold larger among patients than controls, but the difference was not significant (p > 0.05). Riboflavin peak concentrations in plasma (315.6 nmol/l) and times when those concentrations were achieved (3.0 h) were similar to those found for healthy subjects (p > 0.05). Flavocoenzyme peak plasma concentrations were increased 1.4-fold above their baseline levels in cirrhotics which was equal to controls (p > 0.05). 7α-Hydroxyriboflavin was detected in the plasma of patients. Distribution and elimination kinetics of riboflavin were analyzed by using a two-compartment open model; the riboflavin plasma disposition rate constant of the patients (kα = 0. 7232 h-1; k(β) = 0.0627 h-1) were not different from controls (p > 0. 05). No differences between both groups were found regarding renal excretion (renal clearance, first-order rate constants for renal excretion; p > 0.05). In conclusion, patients with cirrhosis of varying etiology and varying medical treatment did not show alterations of riboflavin turnover.

AB - The metabolism of vitamin B2 was studied in five female patients with liver cirrhosis of varying etiology. Following the oral administration of 40 mg (106.3 μmol) riboflavin, plasma concentrations of riboflavin and flavocoenzymes as well as urinary riboflavin excretion were analyzed over a period of 48 h. Results were compared to data obtained for healthy controls (Zempleni J. et al, Am. J Clin. Nutr., 1996 [15]). About 18% of the administered vitamin was recovered from patients' urine, indicating an absorption similar to healthy subjects (p > 0.05). The area under the riboflavin plasma concentration vs time curve was 1.2-fold larger among patients than controls, but the difference was not significant (p > 0.05). Riboflavin peak concentrations in plasma (315.6 nmol/l) and times when those concentrations were achieved (3.0 h) were similar to those found for healthy subjects (p > 0.05). Flavocoenzyme peak plasma concentrations were increased 1.4-fold above their baseline levels in cirrhotics which was equal to controls (p > 0.05). 7α-Hydroxyriboflavin was detected in the plasma of patients. Distribution and elimination kinetics of riboflavin were analyzed by using a two-compartment open model; the riboflavin plasma disposition rate constant of the patients (kα = 0. 7232 h-1; k(β) = 0.0627 h-1) were not different from controls (p > 0. 05). No differences between both groups were found regarding renal excretion (renal clearance, first-order rate constants for renal excretion; p > 0.05). In conclusion, patients with cirrhosis of varying etiology and varying medical treatment did not show alterations of riboflavin turnover.

KW - Blood plasma

KW - Liver cirrhosis

KW - Pharmacokinetics

KW - Riboflavin

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=0029863403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029863403&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 237

EP - 243

JO - Internationale Zeitschrift fur Vitaminforschung. International journal of vitamin research. Journal international de vitaminologie

JF - Internationale Zeitschrift fur Vitaminforschung. International journal of vitamin research. Journal international de vitaminologie

SN - 0300-9831

IS - 3

ER -